CH BIOTECH SER (08037) saw its stock price plummet 5.88% in pre-market trading on Thursday, despite announcing improved interim results for 2025. The biotech company reported a significant narrowing of losses and an increase in revenue, yet investors seemed unimpressed by the financial performance.

According to the interim results released late Wednesday, CH BIOTECH SER's revenue climbed 19.79% year-on-year to HK$38.872 million. The company successfully reduced its loss attributable to owners by 59.95% to HK$32.006 million, with loss per share standing at HK$0.033. The improved financial performance was primarily attributed to effective cost control measures, which led to an increase in gross profit margin and a reduction in administrative expenses. Additionally, the company benefited from a HK$13.7 million insurance claim compensation related to damage caused by heavy rainfall at its Hainan construction site in 2024.

Despite these seemingly positive developments, the market's negative reaction suggests that investors may have expected even better results or harbor concerns about other factors not addressed in the interim report. The pre-market plunge indicates that traders are reassessing the company's valuation and growth prospects in light of the latest financial data. It remains to be seen whether CH BIOTECH SER can reverse this downward trend during regular trading hours and convince investors of its long-term potential in the competitive biotech sector.